Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Dec 29;55(2):196-202.
doi: 10.2478/raon-2020-0072.

The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors

Tomaz Smrkolj  1   2 , Urska Cegovnik Primozic  3 , Teja Fabjan  3 , Sasa Sterpin  3 , Josko Osredkar  3   4
Affiliations
Comparative Study

The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors

Tomaz Smrkolj et al. Radiol Oncol. .

Abstract

Background: Cystoscopy in complement with urinary cytology represents the gold standard for the follow-up of patients with urinary bladder tumours. Xpert Bladder Cancer Monitor Test (XBC) is a novel mRNA-based urine test for bladder cancer surveillance. The aim of the study was to evaluate the performance of the XBC and voided urinary cytology (VUC) in the follow-up of bladder tumours.

Patients and methods: The XBC was performed on stabilized voided urine and VUC was performed on urine samples. The results were compared to cystoscopic findings and histopathological results after transurethral resection of the bladder lesion.

Results: For the prediction of malignant histopathological result sensitivity, the specificity and negative predictive value were 76.9%, 9 7.5% and 93.0% for the XBC and 38.4%, 9 7.5% and 83.3%, respectively for VUC. For the prediction of suspicious or positive cystoscopic finding sensitivity, the specificity and negative predictive value were 75.0%, 95.2%, and 93.0% respectively for the XBC and 41.7%, 97.6%, and 85.4% for VUC. The sensitivities for papilary urothelial neoplasms of low malignant potential (PUNLMP), low- and high-grade tumours were 0.0%, 66.7% an d 100.0% for the XBC and 0.0%, 66 .7% and 42.9%, respectively for VUC.

Conclusions: The XBC showed significantly higher overall sensitivity and negative predictive value than VUC and could be used to increase the recommended follow-up cystoscopy time intervals. Complementing the XBC and voided urinary cytology does not improve performance in comparison to the XBC alone.

Keywords: Xpert BC Monitor Test; cystoscopy; urinary bladder neoplasm; voided urinary cytology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC curve for predicting cystoscopic finding.
Figure 2
Figure 2
ROC curve for histology prediction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. doi. - DOI - PubMed
    1. Mariappan P, Fineron P, O’Donnell M, Gailer RM, Watson DJ, Smith G. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. World J Urol. 2020. et al. Ahead of print. doi. - DOI - PMC - PubMed
    1. Babjuk M, Burger M, Compérat E, Gontero P, Mostafid AH, Palou J. European Association of Urology Guidelines 2020 Edition. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2020. et al. Presented at the EAU Annual Congress Amsterdam 2020.
    1. Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33:66. doi: 10.1016/j.urolonc.2014.06.008. e25-31. doi. - DOI - PubMed
    1. Trinh TW, Glazer DI, Sadow CA, Sahni VA, Geller NL, Silverman SG. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdom Radiol. 2018;43:663–71. doi: 10.1007/s00261-017-1249-6. doi. - DOI - PubMed

Publication types

MeSH terms